Treatment of stable angina pectoris by ivabradine in every day practice: The REDUCTION Study
Received 16 March 2009; accepted 5 June 2009.
Background
The antianginal efficacy of ivabradine was studied in controlled clinical trials. Strict patient selection criteria may cause a discrepancy between the results of highly controlled clinical trials and everyday routine practice. The objective of this study was to evaluate the efficacy and safety of ivabradine in everyday routine practice.
Methods
In this multicenter study, 4,954 patients with stable angina pectoris received ivabradine in everyday routine practice and underwent follow-up for 4 months. The heart rate (HR), angina pectoris attacks, nitrate consumption, overall efficacy, and tolerance were evaluated.
Results
Within 4 months of treatment with ivabradine, HR was reduced by 12.4 ± 12.2 beat/min from 82.9 ± 15.3 to 70.4 ± 9.2 beat/min (P < .0001). Angina pectoris attacks were reduced from 2.4 ± 3.1 to 0.4 ± 1.5 per week (P < .0001). Consumption of short-acting nitrates was reduced from 3.3 ± 4.4 to 0.6 ± 1.6 U/wk (P < .0001). Seventy-eight cases of adverse drug reactions were reported. The most common adverse drug reactions were nausea (n = 11, 0.22%) and dizziness (n = 9, 0.18%). Efficacy and tolerance were graded by physicians as being “excellent/very good” for 97% and 98% of the patients treated.
Conclusion
Ivabradine reduces the HR and is highly effective and well tolerated in the treatment of patients with symptomatic coronary artery disease. The results confirm the findings of controlled clinical trials in a broad patient population in everyday routine practice.
University Heart Center Hamburg, Clinic for Cardiology and Angiology, Martinistrasse 52, Hamburg, Germany
Reprint requests: Ralf Köster, MD, University Heart Center, Clinic for Cardiology and Angiology Martinistrasse 52, 20246 Hamburg.
ABSTRACT